Related Experiment Video
Updated: Aug 7, 2026
08:14
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
[Screening for lung cancer in 2006: is there a validated test?]
1Service d'oncologie, Département de médecine interne, HUG, 1211 Genève 14. nicolas.mach@hcuge.ch
Revue Medicale Suisse
|June 17, 2006
Summary
Lung cancer screening using radiography, sputum cytology, or low-dose CT scans has not yet decreased mortality rates. Current evidence does not support lung cancer screening recommendations.
Area of Science:
- Oncology
- Radiology
- Pulmonology
Context:
- Lung cancer is a leading cause of cancer death, often diagnosed at late stages.
- Surgical treatment is only effective for localized disease.
- Early screening efforts have not reduced mortality.
Purpose:
- To review current data on lung cancer screening techniques.
- To evaluate the effectiveness of screening in reducing lung cancer mortality.
- To determine if screening for lung cancer can be recommended.
Summary:
- Several large trials in the 1980s using radiography and sputum cytology failed to show a significant decrease in lung cancer mortality.
- Improvements in medical imaging have raised hopes for low-dose CT scans as an effective screening tool.
- Despite increased sensitivity in detecting smaller tumors, no screening technique has demonstrated an impact on lung cancer mortality.
Impact:
- As of 2006, screening for lung cancer is not recommended due to lack of demonstrated mortality benefit.
- Further research and advancements in screening technology are needed.
- Early diagnosis remains a challenge for effective lung cancer treatment.
